A new drug combo for head and neck cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests two drugs, GV20-0251 and Sintilimab, given before surgery for head and neck cancer. The goal is to see if this combination can shrink tumors and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a newly diagnosed, advanced head and neck cancer (not nasopharyngeal, salivary gland, or thyroid) that can be removed with surgery.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and clotting functions are within acceptable ranges.
- You have not had prior treatment with certain immune or targeted therapies, and you are not taking high-dose steroids or other immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two medications given before surgery for head and neck cancer. The goal is to see if shrinking the tumor beforehand improves outcomes. If you have operable head and neck squamous cell cancer and are generally healthy, you may be eligible.
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests whether giving an immunotherapy drug called sintilimab before and after surgery can help treat head and neck cancer. The drug aims to boost your immune system to fight the cancer, and the goal is to improve outcomes when combined with the standard surgical treatment.
This trial tests a combination of an immunotherapy drug (sintilimab) with radiation and chemotherapy for people with advanced head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.